greatgenes

Example report: what a greatgenes report looks like

Below is an excerpt from a real greatgenes report, produced by the same analysis engine that runs in your browser — but on a synthetic file, not a real person. Each section is preceded by a short note on what it means.

The file
a file in 23andMe raw-data format, generated by greatgenes: genotypes drawn at random from the allele frequencies of a European reference sample (1000 Genomes), at the positions the report reads
Set on purpose
a few variants, so that every section has something to show: CYP2C19*2 and SLCO1B1*5 (one copy each), one copy of an ACADM variant (carrier), APOE e3/e3, blood group A, light eyes — all listed in the file header
Not shown
Lifestyle and nutrition; Sensitive results (three collapsed blocks: Alzheimer’s disease risk, Parkinson’s disease risk and the ACMG secondary-findings genes — present in every report, so their presence tells nothing); Matches without an explanation; Checked, no signs found (which well-known variants were read and found clear); About your data; Sources with licences and database versions; Not shown.

To see the full report on this file, press “Try a sample” on the home page: it is built in your browser in about a minute, and you can save it as HTML or PDF.

File: greatgenes-sample-23andme, analysed on 2026-10-21.

Sample report on a synthetic file — not a real person. The genotypes in this file were generated by greatgenes from allele frequencies in a European reference sample; a few variants were set on purpose to show every section of the report. It shows what a report looks like and says nothing about any person.

For educational and informational purposes only. Not a medical device, not a diagnosis and not medical advice. The results may be incomplete: the program may have missed something. For a more accurate and detailed study, see a medical geneticist — greatgenes does not provide such services.

greatgenes is an information service: this report compares your file with public databases. Consumer chips make errors, especially on rare variants: significant findings should be confirmed by a clinical test, and decisions about treatment are made together with a doctor.

What we read from your file

  • Sex by DNA: female
  • Eye colour (likely): light
  • ABO blood group (likely): A
  • Earwax type (likely): wet
  • Lactose (likely): no signs of intolerance
  • Reference group for calibration: not determined — the file is not close enough to any single 1000 Genomes group, so polygenic-score percentiles are computed against a mix of groups in the proportions estimated from the file (which allele frequencies were used for medicines is stated in the pharmacogenetics section)
  • File: 23andMe, 17996 SNPs read

Age cannot be determined from DNA chip data. If these details don’t match you, the file may not be yours.

Summary

Nothing of practical significance was found in: carrier status (for family planning).
Well-known variants that were checked are listed in the section “Checked, no signs found”.
Results some people prefer not to learn (Alzheimer’s and Parkinson’s disease risk, genes of the ACMG SF v3.3 list) are not part of this summary: they are collapsed in the section “Sensitive results”.

Reliability shows how well the sources support the link between the variant and the description (it is not the probability of a disease): high — clinical guideline (CPIC, DPWG), expert review or several agreeing sources; medium — one reliable source; low — a wiki (SNPedia) or a single study.

(preliminary) — the verified databases give little support for this finding; it needs confirmation.

ReliabilityNext stepFinding
mediumGeneral knowledge: bowel examination (colonoscopy or stool test) follows the usual programmes, earlier if relatives had bowel cancer; the timing can be discussed with a doctor8q24: signs of increased risk of colorectal and prostate cancer were found (~1.2× per allele, per GWAS Catalog)
mediumGeneral knowledge: a lipid profile and blood pressure can be discussed with a doctor; smoking increases coronary heart disease risk9p21: signs of increased coronary heart disease risk were found (~1.25–1.5×, per GWAS Catalog)
mediumGeneral knowledge: smoking increases this risk; after age 55, a fundus examination every 1–2 years can be discussed with an ophthalmologistCFH Y402H: signs of increased risk of age-related macular degeneration were found (per GWAS Catalog)
mediumGeneral knowledge: after age 40, intraocular pressure can be measured at an eye examination on requestLOXL1: signs of increased risk of pseudoexfoliation glaucoma were found (per GWAS Catalog)
lowThe Endocrine Society (2024) does not recommend routine vitamin D testing in healthy adults. General knowledge: a 25(OH)D test can be discussed with a doctorGC: per GWAS Catalog, a tendency to lower vitamin D (preliminary)
Details
FindingGenotypesSourcesPriority
8q24rs6983267 GTSNPedia2
9p21rs1333049 CCClinVar, SNPedia2
CFH Y402Hrs1061170 CCSNPedia3
LOXL1rs2165241 CT, rs3825942 GGClinVar, SNPedia3
GCrs2282679 GTSNPedia3

Traits

ReliabilityNext stepFinding
lowQC check traitHERC2: light eye genotype (blue/grey/green), per SNPedia
Details
FindingGenotypesSourcesPriority
HERC2rs12913832 GGClinVar, SNPedia4

Medications (pharmacogenetics)

Pharmacogenetics shows how your genes affect the way your body handles some medicines; this is useful when a doctor chooses a drug or a dose. Never start, stop or change a medicine on your own because of this report.

ReliabilityNext stepFinding
highCPIC states: the starting warfarin dose is below average and is calculated with a genotype-based dosing calculator; discuss with your doctorVKORC1 -1639 G/A: intermediate warfarin sensitivity (CPIC)
highPer CPIC, considered together with VKORC1CYP4F2 V433M: per CPIC, slightly higher warfarin requirement
mediumDPWG (irinotecan) states no dose change; CPIC (atazanavir) states no restrictions. A single tag SNP does not determine the diplotypeUGT1A1 rs887829 (*80) — tag of the *28 allele, one copy: intermediate activity; Gilbert syndrome is usually not expected from this genotype (DPWG, CPIC)
Details
FindingGenotypesSourcesPriority
VKORC1 -1639 G/Ars9923231 CTClinVar, SNPedia2
CYP4F2 V433Mrs2108622 CTClinVar3
UGT1A1 rs887829 (*80)rs887829 CTgreatgenes3

Pharmacogenetics: drug metabolism type (CPIC)

For each gene, alleles were inferred from the SNPs in your file and matched to the CPIC tables (alleles → diplotype → phenotype; CPIC data as of 2026-10-13). This is a comparison with guidelines, not a clinical test: the chip reads only some of the variants, cannot see gene duplications or deletions and does not show which of the two chromosome copies carries each variant. If a variant required for the gene was not read in the file, or the variants allow several explanations, no phenotype is given; if other variants of the gene were not read, the phenotype is given and the notes state how many alleles were not checked. Recommendations are summaries of the CPIC guidelines for the named phenotype; decisions about medication are made together with a doctor, if needed after a clinical test. Where the chip cannot tell allele combinations apart, their likelihood is weighed with CPIC allele frequencies of the population groups compatible with your file: American, European, Latino, Near Eastern.

GeneAlleles from the file's SNPsMetabolism type / function (CPIC)What the source states
CYP2C19*1/*2intermediate metaboliserCPIC states for this phenotype: in acute coronary syndrome and stenting, prasugrel or ticagrelor rather than standard-dose clopidogrel if possible and not contraindicated; for neurovascular indications, another P2Y12 inhibitor at standard dose if possible; citalopram, escitalopram, sertraline — usual starting dose, slower titration and a lower maintenance dose; omeprazole, lansoprazole, pantoprazole, dexlansoprazole — standard starting dose, for use longer than 12 weeks the dose may be reduced by 50%; voriconazole and amitriptyline — usual doses. Discuss with your doctor.
CYP2C9*1/*1normal metaboliser (activity score 2.0)Recommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.
SLCO1B1*1/*5decreased transporter functionCPIC states for this phenotype: simvastatin and lovastatin — another statin if possible (if needed, simvastatin below 20 mg and lovastatin not above 20 mg a day); atorvastatin — starting dose not above 40 mg; pitavastatin — not above 2 mg; rosuvastatin, pravastatin, fluvastatin — usual starting dose, bearing in mind the higher risk of myopathy at high doses. Discuss with your doctor.
TPMT*1/*1normal metaboliserRecommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.
NUDT15*1/*1normal metaboliserRecommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.
DPYDreference/referencenormal metaboliser (activity score 2.0)Recommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.
CYP3A5*3/*3poor metaboliserRecommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.
CYP2B6*1/*1normal metaboliserRecommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.
CYP2D6—not determined: required variants were not read in the file (rs3892097)No recommendation shown: the file does not contain enough data
G6PDB (reference)/B (reference)normal G6PD activityRecommendations for this phenotype are not summarised in the report: per the CPIC guideline, for most drugs these are standard doses.

Notes to the table:

  • CYP2C19 (positions read: 26/43): Variants found: rs4244285 (*2) — one copy. Less likely combinations by allele frequencies (CPIC or 1000 Genomes/gnomAD) that the chip does not exclude (the phase of variants is unknown or the allele is not read by the chip): *2/*9 (likely poor metaboliser); their probability is below 5% in every population considered from the frequency tables. The chip does not read common alleles with altered function: *9 (insertions, deletions or positions missing from the file). A copy read as *1 may be one of them — this is included in the phenotype probability using allele frequencies (CPIC or 1000 Genomes/gnomAD) in every population (ancestry is unknown from the file); this is clarified by a clinical test. Alleles with altered function not checked: 3 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): *9. For sertraline CPIC uses CYP2C19 and CYP2B6 together; for tricyclic antidepressants, together with CYP2D6.
  • CYP2C9 (positions read: 39/85): Less likely combinations by allele frequencies (CPIC or 1000 Genomes/gnomAD) that the chip does not exclude (the phase of variants is unknown or the allele is not read by the chip): *1/*42 (intermediate metaboliser); *42/*42 (poor metaboliser); their probability is below 5% in every population considered from the frequency tables. The chip does not read common alleles with altered function: *42 (insertions, deletions or positions missing from the file). A copy read as *1 may be one of them — this is included in the phenotype probability using allele frequencies (CPIC or 1000 Genomes/gnomAD) in every population (ancestry is unknown from the file); this is clarified by a clinical test. Alleles with altered function not checked: 13 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): *42. For warfarin, CPIC uses CYP2C9 together with VKORC1 (and CYP4F2 in people of European ancestry) — see the VKORC1 and CYP4F2 rows in the Medications section.
  • SLCO1B1 (positions read: 22/35): Variants found: rs4149056 (*5; *15; *45) — one copy. Less likely combinations by allele frequencies (CPIC or 1000 Genomes/gnomAD) that the chip does not exclude (the phase of variants is unknown or the allele is not read by the chip): *5/*45 (poor transporter function); *45/*45 (poor transporter function); their probability is below 5% in every population considered from the frequency tables. The chip does not read common alleles with altered function: *45 (insertions, deletions or positions missing from the file). A copy read as *1 may be one of them — this is included in the phenotype probability using allele frequencies (CPIC or 1000 Genomes/gnomAD) in every population (ancestry is unknown from the file); this is clarified by a clinical test. Alleles with altered function not checked: 1 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): *45. For rosuvastatin CPIC also uses ABCG2, and for fluvastatin CYP2C9.
  • TPMT (positions read: 24/43): Less likely combinations by allele frequencies (CPIC or 1000 Genomes/gnomAD) that the chip does not exclude (the phase of variants is unknown or the allele is not read by the chip): *8/*8 (intermediate metaboliser); their probability is below 5% in every population considered from the frequency tables. The chip does not read common alleles with altered function: *8 (insertions, deletions or positions missing from the file). A copy read as *1 may be one of them — this is included in the phenotype probability using allele frequencies (CPIC or 1000 Genomes/gnomAD) in every population (ancestry is unknown from the file); this is clarified by a clinical test. Alleles with altered function not checked: 20 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): *8. For thiopurines CPIC uses TPMT and NUDT15 together.
  • NUDT15 (positions read: 3/16): Less likely combinations by allele frequencies (CPIC or 1000 Genomes/gnomAD) that the chip does not exclude (the phase of variants is unknown or the allele is not read by the chip): *1/*6 (intermediate metaboliser); *6/*6 (poor metaboliser); their probability is below 5% in every population considered from the frequency tables. The chip does not read common alleles with altered function: *6 (insertions, deletions or positions missing from the file). A copy read as *1 may be one of them — this is included in the phenotype probability using allele frequencies (CPIC or 1000 Genomes/gnomAD) in every population (ancestry is unknown from the file); this is clarified by a clinical test. Alleles with altered function not checked: 10 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): *6.
  • DPYD (positions read: 65/81): Alleles with altered function not checked: 5 (their variants were not read in the file). A normal result does not exclude unchecked alleles. CPIC scores DPYD activity from the two variants with the lowest function and, with two different variants, assumes they are on different copies. Chips read only some DPYD variants; CPIC recommends checking DPYD before fluoropyrimidine treatment, and this is done with a clinical test.
  • CYP3A5 (positions read: 4/6): Variants found: rs776746 (*3) — two copies. Alleles with altered function not checked: 1 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): *7. The CYP3A5*7 allele (a single-nucleotide insertion; up to 12% in people of African ancestry) is not read by chips, and the *6 allele is missing from some chips. An unread *7 or *6 copy looks like *1, that is, active: a *1/*7 carrier looks like *1/*1 on the chip, and *3/*7 looks like *1/*3. So CYP3A5 may appear more active on the chip than it really is; before tacrolimus is prescribed, the phenotype is confirmed by a clinical test.
  • CYP2B6 (positions read: 21/48): Alleles with altered function not checked: 1 (their variants were not read in the file). A normal result does not exclude unchecked alleles. The *18 allele (more common in people of African ancestry) and a number of rare alleles are missing from many chips. For sertraline CPIC uses CYP2B6 and CYP2C19 together.
  • G6PD (positions read: 22/163): Less likely combinations by allele frequencies (CPIC or 1000 Genomes/gnomAD) that the chip does not exclude (the phase of variants is unknown or the allele is not read by the chip): B (reference)/Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (variable G6PD activity (one copy of the variant: in women or when sex is not determined)); Canton, Taiwan-Hakka, Gifu-like, Agrigento-like/Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (G6PD deficiency); their probability is below 5% in every population considered from the frequency tables. The chip does not read common alleles with altered function: Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (insertions, deletions or positions missing from the file). A copy read as B (reference) may be one of them — this is included in the phenotype probability using allele frequencies (CPIC or 1000 Genomes/gnomAD) in every population (ancestry is unknown from the file); this is clarified by a clinical test. Alleles with altered function not checked: 149 (their variants were not read in the file). A normal result does not exclude unchecked alleles. Common ones among them (at least 1% in at least one population according to CPIC or 1000 Genomes/gnomAD): Canton, Taiwan-Hakka, Gifu-like, Agrigento-like. G6PD is on the X chromosome: men have one copy, and in women with one copy of a variant the enzyme activity varies. More than 150 G6PD variants are known and the chip reads few of them; G6PD deficiency is reliably determined by an enzyme activity blood test.

Limitations: chips do not read insertions, deletions and repeats (for example UGT1A1*28, CYP2D6*3 and *6) or duplications and deletions of whole genes (CYP2D6*5, duplications); the phase of variants is unknown — all compatible combinations are considered; some alleles important for particular populations (for example CYP3A5*6 and *7, CYP2B6*18, CYP2C9*5, *6, *8, *11 in people of African ancestry; NUDT15*3 in people of East Asian and Latin American ancestry) are missing from many chips. Not covered: UGT1A1 (*28 is a repeat the chip cannot read; CPIC allows the rs887829 (*80) marker as a stand-in for *28, but in the phenotype tables *80 without *28 has "unknown function", so the UGT1A1 metabolism type is not determined here; the rs887829 rows are in the Medications section), HLA-A and HLA-B (the guidelines do not support typing from chip SNPs), IFNL3 (the recommendation concerns hepatitis C regimens that are hardly used any more), NAT2 (hydralazine, isoniazid — separate rows of the Medications section), RYR1 and CACNA1S (findings are in the ClinVar sections), MT-RNR1 and VKORC1/CYP4F2 (separate rows of the Medications section, if variants are found). DPWG recommendations are not yet included in this section.

Polygenic scores

A polygenic score adds up the small effects of many variants linked to a trait or a disease. It is a relative research measure, not the probability of getting a disease. Your file is not close enough to any single 1000 Genomes group, so the percentile is computed against a mix of these reference groups in the proportions estimated from your file (see “What we read from your file”).

Caveat: the scores themselves were built mostly on studies of people of European ancestry. The percentile honestly shows where you stand among people of your reference group, but the link between a score and the trait is weaker in other groups (most of all in the African group), so the words “above/below average” mean less here than they do for the European group.

TraitYour resultReliability
Kidney stoneswell above averagemedium
Bone mineral density (heel)above averageadequate
Insomniabelow averageadequate
Osteoarthritis (knee and hip)below averageadequate
Waist-to-hip ratiobelow averageadequate
LDL cholesterolbelow averageadequate
Goutbelow averagemedium
Resting heart rateabove averagemedium
Basal cell carcinomaabove averagemedium
Dupuytren's contractureabove averagemedium
Hypothyroidismabove averageadequate
Uric acidbelow averageadequate
Details

Traits about average: 39; not assessed (score coverage below 50 %): 0. The full table is below.

A polygenic score is the sum of contributions of variants that GWAS Catalog and PGS Catalog associate with a disease or a measurement. The percentile is a computed position among people with the same mix of 1000 Genomes groups as estimated from your file: the expected frequency of each allele is the average over the five groups weighted by those proportions, and the average and spread of the sum are computed from these frequencies assuming Hardy–Weinberg equilibrium; for the published score the spread is corrected for linkage between variants using the real genotypes of the group participants. 50% is the middle, 84% means the sum is higher than in 84% of people (z = +1). In brackets, the score's coverage and the number of SNPs found: coverage is the share of the score's spread (variance) between people that the variants found on the chip account for; the percentile is shown only if at least 50% of the score's variance is covered. The scores agree if the z-scores of the two methods differ by less than 1.

Limitations: this is a relative research measure, not the probability of developing a disease; lifestyle and family history weigh as much or more. Scores with few SNPs ("low" reliability) rest on 1–2 variants. The scores are built mostly from studies of people of European ancestry: for people of other ancestry the percentile may be shifted and the accuracy of the scores is considerably lower.

TraitGWAS: percentile (z)SNPsReliabilityPGS: percentile (coverage)Sum of contributions
Kidney stones99.6 % (+2.62)12medium—well above average
Bone mineral density (heel)95.0 % (+1.64)111adequate—genetically above
Insomnia6.6 % (-1.51)151adequate—below average
Osteoarthritis (knee and hip)7.1 % (-1.47)55adequate—below average
Waist-to-hip ratio7.2 % (-1.46)192adequate—genetically below
LDL cholesterol68.4 % (+0.48)184adequate7.8% (87.9% of variance, 162 of 223 SNPs); score reliability: adequatenear average — scores disagree
Gout7.0 % (-1.47)72adequate8.5% (80.6% of variance, 51 of 216 SNPs); score reliability: mediumbelow average — scores agree
Resting heart rate91.6 % (+1.38)49medium—genetically above
Basal cell carcinoma89.7 % (+1.27)44medium—above average
Dupuytren's contracture89.2 % (+1.24)12medium—above average
Hypothyroidism86.7 % (+1.11)91adequate—above average
Uric acid14.2 % (-1.07)130adequate—genetically below
Myocardial infarction84.0 % (+0.99)18medium—near average
Crohn's disease82.3 % (+0.93)112adequate—near average
Triglycerides45.8 % (-0.10)182adequate17.9% (73.2% of variance, 73 of 108 SNPs); score reliability: adequatenear average — scores agree
Uterine fibroids18.8 % (-0.89)37medium—near average
Vitiligo19.6 % (-0.86)32medium—near average
Ulcerative colitis20.3 % (-0.83)83adequate—near average
Haemoglobin21.3 % (-0.80)195adequate—near average
Open-angle glaucoma21.6 % (-0.79)66adequate—near average
Atopic dermatitis (eczema)78.2 % (+0.78)28medium—near average
Chronotype (morning or evening person)77.1 % (+0.74)60adequate—near average
Psoriasis23.3 % (-0.73)52adequate—near average
Type 2 diabetes85.8 % (+1.07)135adequate76.0% (74.8% of variance, 36 of 50 SNPs); score reliability: mediumabove average — scores agree
Rheumatoid arthritis23.8 % (-0.71)41medium—near average
HDL cholesterol20.7 % (-0.82)222adequate75.1% (85.5% of variance, 162 of 223 SNPs); score reliability: adequatenear average — scores disagree
Atrial fibrillation89.6 % (+1.26)127adequate74.5% (62.9% of variance, 8 of 25 SNPs); score reliability: mediumabove average — scores agree
Colorectal cancer20.7 % (-0.82)36medium27.0% (93.2% of variance, 24 of 27 SNPs); score reliability: adequatenear average — scores agree
Coeliac disease2.5 % (-1.96)23medium27.7% (96.1% of variance, 212 of 228 SNPs); score reliability: mediumbelow average — scores partly agree
Type 1 diabetes71.7 % (+0.57)46medium—near average
Age-related macular degeneration60.7 % (+0.27)29medium28.7% (94.8% of variance, 34 of 157 SNPs); score reliability: mediumnear average — scores agree
Age-related hearing loss29.1 % (-0.55)15medium—near average
Iron status (ferritin, serum iron)70.3 % (+0.53)19medium—near average
Glycated haemoglobin (HbA1c)69.8 % (+0.52)127adequate—near average
Cutaneous melanoma65.1 % (+0.39)31medium69.8% (70.6% of variance, 17 of 24 SNPs); score reliability: adequatenear average — scores agree
Coronary artery disease75.9 % (+0.70)30medium30.8% (92.8% of variance, 22 of 27 SNPs); score reliability: adequatenear average — scores partly agree
Migraine68.1 % (+0.47)18medium—near average
Coffee and tea consumption33.2 % (-0.43)15medium—near average
Vitamin D36.8 % (-0.34)39medium—near average
Stroke (ischaemic)62.7 % (+0.33)11medium—near average
Venous thromboembolism25.5 % (-0.66)33medium60.2% (83.0% of variance, 25 of 96 SNPs); score reliability: mediumnear average — scores agree
Multiple sclerosis39.9 % (-0.26)62adequate—near average
Asthma59.5 % (+0.24)50adequate—near average
Systolic blood pressure41.1 % (-0.23)258adequate—near average
Alcohol consumption58.8 % (+0.22)59adequate—near average
Breast cancer51.6 % (+0.04)124adequate42.8% (81.5% of variance, 77 of 86 SNPs); score reliability: adequatenear average — scores agree
Endometriosis57.2 % (+0.18)20medium—near average
Abdominal aortic aneurysm44.8 % (-0.13)13medium—near average
Restless legs syndrome54.5 % (+0.11)21medium—near average
Height54.1 % (+0.10)564adequate—near average
Body mass index49.7 % (-0.01)515adequate—near average

What these traits are:

  • Kidney stones — Hard mineral deposits that form in the kidneys or urinary tract. How much a person drinks and what they eat also matter.
  • Insomnia — Difficulty falling asleep or staying asleep. A higher score means a somewhat greater genetic tendency to such complaints; sleep habits, stress and health matter more.
  • Osteoarthritis (knee and hip) — Wear of joint cartilage that causes pain and stiffness, most often in the knees and hips. Body weight and past joint injuries also matter.
  • Waist-to-hip ratio — Waist size relative to hip size, a measure of where the body stores fat. A higher score means a genetic tendency to store more fat around the waist.
  • LDL cholesterol — The "bad" cholesterol in the blood; higher levels speed up narrowing of the arteries. (PGS000115, Trinder 2020, 223 SNP)
  • Gout — Painful joint inflammation caused by uric acid crystals. (PGS001822, Privé 2022, UK Biobank, 216 SNP)
  • Resting heart rate — Number of heartbeats per minute at rest. A higher score means a genetically slightly faster resting pulse; fitness matters more.
  • Dupuytren's contracture — Thickening of the tissue in the palm that slowly bends one or more fingers towards the palm; more common in men of northern European origin.
  • Triglycerides — Blood fats measured in a standard lipid test; levels depend strongly on diet and alcohol. (PGS003401, Pieri 2022, 108 SNP)
  • Uterine fibroids — Non-cancerous growths in the muscle of the womb, very common after 30; many cause no symptoms. Shown only when the DNA file indicates female sex.
  • Vitiligo — An immune condition in which patches of skin lose their pigment.
  • Haemoglobin — The oxygen-carrying protein of red blood cells, together with the haematocrit (the share of blood volume taken up by red cells). A higher score means genetically somewhat higher values.
  • Atopic dermatitis (eczema) — An itchy inflammatory skin condition that often starts in childhood and is common in families with allergies and asthma.
  • Chronotype (morning or evening person) — Whether a person naturally prefers mornings ("lark") or evenings ("owl"). A higher score means a genetic tendency towards being a morning person.
  • Type 2 diabetes — High blood sugar due to a reduced response to insulin; weight and physical activity matter a lot. (PGS004226, Liu 2023, 50 SNP)
  • HDL cholesterol — The "good" cholesterol in the blood, measured in a standard lipid test. (PGS004914, Trinder 2019, 223 SNP)
  • Atrial fibrillation — An irregular heart rhythm that raises the risk of stroke. (PGS012580, Zheng 2024, 25 SNP)
  • Colorectal cancer — Cancer of the colon or rectum. (PGS000146, Hsu 2015, 27 SNP)
  • Coeliac disease — An immune reaction to gluten that damages the small intestine. The score combines HLA-DQ variants, which almost everyone with coeliac disease carries, with non-HLA variants. (PGS000040, Abraham 2014, 228 SNP)
  • Age-related macular degeneration — Damage to the centre of the retina that blurs central vision, usually after the age of 60. (PGS001834, Privé 2022, UK Biobank, 157 SNP)
  • Age-related hearing loss — Gradual loss of hearing with age. Exposure to loud noise also matters a lot.
  • Iron status (ferritin, serum iron) — Blood measures of the body's iron stores: ferritin, serum iron and transferrin saturation. A higher score means genetically somewhat higher iron levels; HFE variants (haemochromatosis) are described separately.
  • Cutaneous melanoma — The most dangerous type of skin cancer; sun exposure and fair skin add to the risk. (PGS000079, Graff 2021, 24 SNP)
  • Coronary artery disease — Narrowing of the heart's arteries that can lead to angina and heart attack. (PGS000010, Mega 2015, 27 SNP)
  • Migraine — Recurrent headache attacks, often on one side and with sensitivity to light or sound, sometimes preceded by an aura.
  • Coffee and tea consumption — How much coffee and tea people tend to drink. Part of the signal comes from how quickly the body breaks down caffeine (CYP1A2 and AHR genes); this is a habit, not a health measure.
  • Venous thromboembolism — Blood clots in the deep veins of the legs (deep vein thrombosis) or in the lungs (pulmonary embolism). (PGS001277, Tanigawa 2022, UK Biobank, 96 SNP)
  • Alcohol consumption — How much alcohol people tend to drink, as reported in large studies. This describes a drinking habit, not alcohol dependence; a higher score means a genetic tendency to drink somewhat more.
  • Breast cancer — The most common cancer in women. The score was developed for women and is shown only when the DNA file indicates female sex. (PGS000028, Shieh 2016, 83 SNP)
  • Endometriosis — Tissue similar to the lining of the womb growing outside it, which can cause pelvic pain. Shown only when the DNA file indicates female sex.
  • Restless legs syndrome — An urge to move the legs with unpleasant sensations, usually in the evening or at night. Low iron stores can make it worse.
  • Height — Adult body height. A higher score means a genetic tendency to be taller; each of hundreds of variants adds only a few millimetres.

ClinVar findings with an automatic explanation

Variants marked as pathogenic or likely pathogenic (per ClinVar) for which greatgenes has no hand-written explanation. The explanation for each finding was assembled automatically from a template using information from public databases and has not been reviewed by a specialist. Consumer chips often make errors on rare variants: such findings should be confirmed by a clinical test and are worth discussing with a clinical geneticist.

ReliabilityNext stepFinding
highYou may want to discuss this with a doctor.The variant rs77931234 in the ACADM gene is classified as pathogenic or likely pathogenic for the condition "MCADD - Medium-chain acyl-CoA dehydrogenase deficiency – full ACADM sequencing newborn screening follow up"; several laboratories gave the same classification (per ClinVar). Genotype AG: one copy of the variant (heterozygous). About the ACADM gene (per MedlinePlus): The ACADM gene provides instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). This enzyme functions within mitochondria, the energy-producing centers in cells. MCAD is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy. Consumer chips often make errors on rare variants; the finding is worth confirming with a clinical test and discussing with a clinical geneticist (general knowledge).
Details
FindingGenotypesSourcesPriority
The variant rs77931234 in the ACADM gene is classified as pathogenic or likely pathogenic for the condition "MCADD - Medium-chain acyl-CoA dehydrogenase deficiency – full ACADM sequencing newborn screening follow up"rs77931234 AGClinVar, SNPedia1

See the whole report

The full report on this file — with the sections left out here — takes about a minute in your browser. Nothing is uploaded, and the report carries the same “synthetic sample” banner as the excerpt above. To try your own raw DNA data instead, choose your file on the home page.

Try it in your browser Analyse your own file

The sample file itself: greatgenes-sample-23andme.txt (0.5 MB, synthetic). Page last updated on 2026-10-21.